JP Morgan Maintains Neutral on Quest Diagnostics, Raises Price Target to $250

Benzinga Newsdesk www.benzinga.com Neutral 49.2%

Neg 0% Neu 49.2% Pos 0%

JP Morgan analyst Lisa Gill maintains Quest Diagnostics (NYSE:DGX) with a Neutral and raises the price target from $220 to $250.